A preliminary study of erythropoietin for anemia associated with ribavirin and interferon-α [9]

American Journal of Gastroenterology

Volumn 96, Issue 9 SUPPL., 2001, Pages 2802-2804

  Talal, A H ^b   Weisz, K ^b   Hau, T ^b   Kreiswirth, S ^b   Dieterich, D T ^a  

^a Liberty Medical LLP   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; RECOMBINANT ERYTHROPOIETIN; RIBAVIRIN;

ANEMIA; CLINICAL TRIAL; DRUG EFFICACY; DRUG INDUCED DISEASE; HEMOGLOBIN DETERMINATION; HEMOLYSIS; HEPATITIS C; HUMAN; LETTER; MAJOR CLINICAL STUDY; PRIORITY JOURNAL;

EID: 0034821017     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9270(01)02711-3     Document Type: Letter

References (7)

1. National Institutes of Health Consensus Development Conference Panel statement: Management of hepatitis C
2. Changes in hemoglobin during therapy with interferon alfa-2b plus ribavirin in INFα-naive and IFNα-experienced patients
3. Inhibition of erythropoietin production by cytokines: Implications for the anemia involved in inflammatory states
4. Interferon-α inhibits erythropoietin-induced proliferation, but not differentiation, and restricts erythroleukemia development
5. Inhibitory effects of zidovudine in erythroid progenitor cells: Reversal with a combination of erythropoietin and interleukin-3
6. Indications and guidelines for the use of hematopoietic growth factors
7. Recombinant erythropoietin for zidovudine-induced anemia in AIDS